Wed, Dec 24, 2014, 8:03 PM EST - U.S. Markets closed early today

Recent

% | $
Quotes you view appear here for quick access.

Elan Corporation, plc Message Board

  • rjmcbear rjmcbear May 20, 2005 9:32 AM Flag

    New read about Tysabri

    May 20, 2005 (The News & Observer - Knight Ridder/Tribune Business News via COMTEX) -- Eleven weeks after Biogen Idec pulled its much-touted multiple sclerosis drug off the market because of health risks, two questions still
    loom: Will the drug return and how long will the company continue to make it at its
    Research Triangle Park facility?

    So far, there are no clear answers to either.

    The first new type of MS drug to become available in years, Tysabri promised new
    hope for patients and offered blockbuster potential for Biogen Idec. The company
    hired about 300 in the Triangle last year, a majority of them to manufacture Tysabri.

    Now, patients, investors and Biogen Idec employees are waiting for the results
    of a safety evaluation that will help determine whether Biogen Idec brings
    the drug back to market.

    "Everybody is trying to find out," the status of the drug, said Soham Pandya, an analyst with Susquehanna Financial Group in New York.

    Meanwhile, the company's top local official gives carefully guarded answers to questions about whether production of the drug is ongoing.

    "We're in a pause mode," said Glen Williams, general manager of Biogen Idec's
    RTP operations, in a phone interview. "This type of plant you don't just start
    and stop."

    But he did offer a hint of what's to come.

    This summer, Biogen Idec plans to test a method to increase the amount of Tysabri the RTP plant can generate without lengthening production time. If the test pans out, because of regulatory requirements, it would take about a year before the method could be used for commercial production.

    Production levels of the drug signal the likelihood of Biogen Idec reintroducing
    it, said Pandya.

    That Biogen Idec plans to run the test indicates the company believes there's a
    good chance Tysabri will return to the market, maybe as early as next year, Pandya said.

    "It's a difficult time for the company right now," he said. "But they seem to be
    doing the right thing."

    Biogen Idec took Tysabri off the market Feb. 29 because it was linked to a fatal
    nervous system disorder. The recall came just two months after Tysabri hit the market and the RTP facility had just started an eight-week production cycle.

    While the company wrestles with the drug's future, MS patients remain in limbo.

    Lise Cagle worries about the possible side effects of Tysabri, but said she remains interested in whether the company will bring the drug back.

    Cagle, who was diagnosed with MS in 1998 and has unsuccessfully tried three of
    the four older MS drugs, never received her first injection of Tysabri. But next
    week, the Raleigh woman plans to talk to her neurologist, who had recommended the drug before the recall.

    "I want it to be safe, so if I really need something it would be available," Cagle said. "I'm doing really well now and I'm not taking any medication. If I had problems, I'd probably be more anxious for it to come back to the market."

    About four months after the Food and Drug Administration approved Tysabri for sale, Biogen Idec received reports about possible side-effects. To date, three cases of progressive multifocal leukoencephalopathy have been confirmed among about 8,000 patients who took Tysabri. Also known as PML, the rare
    disorder causes mental deterioration, vision loss, paralysis and, within about four
    months, death.

    Now, everything hinges on the safety .....

    By Sabine Vollmer

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.